JP2011510653A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510653A5
JP2011510653A5 JP2010545015A JP2010545015A JP2011510653A5 JP 2011510653 A5 JP2011510653 A5 JP 2011510653A5 JP 2010545015 A JP2010545015 A JP 2010545015A JP 2010545015 A JP2010545015 A JP 2010545015A JP 2011510653 A5 JP2011510653 A5 JP 2011510653A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010545015A
Other languages
Japanese (ja)
Other versions
JP2011510653A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000554 external-priority patent/WO2009097119A2/en
Publication of JP2011510653A publication Critical patent/JP2011510653A/ja
Publication of JP2011510653A5 publication Critical patent/JP2011510653A5/ja
Pending legal-status Critical Current

Links

JP2010545015A 2008-01-29 2009-01-28 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定 Pending JP2011510653A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2424108P 2008-01-29 2008-01-29
PCT/US2009/000554 WO2009097119A2 (en) 2008-01-29 2009-01-28 Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014017760A Division JP6324092B2 (ja) 2008-01-29 2014-01-31 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定

Publications (2)

Publication Number Publication Date
JP2011510653A JP2011510653A (ja) 2011-04-07
JP2011510653A5 true JP2011510653A5 (enExample) 2011-09-08

Family

ID=40913463

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010545015A Pending JP2011510653A (ja) 2008-01-29 2009-01-28 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定
JP2014017760A Active JP6324092B2 (ja) 2008-01-29 2014-01-31 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定
JP2015222014A Pending JP2016027828A (ja) 2008-01-29 2015-11-12 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定
JP2017178253A Active JP6665141B2 (ja) 2008-01-29 2017-09-15 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定
JP2018232409A Pending JP2019041772A (ja) 2008-01-29 2018-12-12 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014017760A Active JP6324092B2 (ja) 2008-01-29 2014-01-31 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定
JP2015222014A Pending JP2016027828A (ja) 2008-01-29 2015-11-12 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定
JP2017178253A Active JP6665141B2 (ja) 2008-01-29 2017-09-15 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定
JP2018232409A Pending JP2019041772A (ja) 2008-01-29 2018-12-12 CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定

Country Status (6)

Country Link
US (3) US9090875B2 (enExample)
EP (2) EP3363893B1 (enExample)
JP (5) JP2011510653A (enExample)
CA (1) CA2713462C (enExample)
ES (2) ES2666667T3 (enExample)
WO (1) WO2009097119A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666667T3 (es) * 2008-01-29 2018-05-07 Fred Hutchinson Cancer Research Center Identificación de células T CD8+ que son CD161 hi y/o IL-18R (alfa) hi y tienen una capacidad de evacuación rápida de fármacos
WO2012015662A1 (en) * 2010-07-27 2012-02-02 Baylor Research Institute Il-18 receptor as a novel target of regulatory t cells in cancer
CA2846074A1 (en) * 2011-08-31 2013-05-10 Alexzander A. Asea Compositions and methods for treatment of metastatic cancer
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
WO2014039044A1 (en) 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
AU2013379773B2 (en) * 2013-03-01 2018-04-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
LT3132247T (lt) 2014-04-16 2021-12-10 Juno Therapeutics Gmbh Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės
IL313845A (en) 2014-04-23 2024-08-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
CN105754938A (zh) * 2014-12-17 2016-07-13 四川新生命干细胞科技股份有限公司 一种从脐带血中分离单个核细胞的试剂盒及方法
AU2016297605A1 (en) * 2015-07-21 2018-02-15 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
CN108474791B (zh) 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
EP3548048A4 (en) * 2016-12-02 2020-07-01 Cartesian Therapeutics, Inc. CANCER IMMUNOTHERAPY WITH CD8 + HIGHLY ENRICHED CHIMERIC ANTIGEN RECEPTOR T CELLS
EP3710039A4 (en) * 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
BR112020023336A2 (pt) * 2018-05-15 2021-03-16 Case Western Reserve University Receptor de antígeno quimérico de longa vida (car) que expressa células t para terapia de câncer
AU2020379848A1 (en) 2019-11-06 2022-05-19 Baylor College Of Medicine Method for producing cytotoxic effector memory T cells for T-cell treatment of cancer
WO2022109340A1 (en) * 2020-11-20 2022-05-27 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Immunomodulatory clinical biomarker profiles and uses thereof
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
WO2022153295A1 (en) * 2021-01-12 2022-07-21 Hadasit Medical Research Services & Development Ltd. Improved adoptive cell transfer therapy for cancer
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB9314623D0 (en) 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6630576B2 (en) 1998-04-03 2003-10-07 Pennsylvania State Research Foundation Amino acid substitution mutants of interleukin 13
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
EP1621551A1 (en) 2004-07-27 2006-02-01 Centre National De La Recherche Scientifique Use of LLT1 and/or CD161 for modulating the activity of cells of the immune system
ES2666667T3 (es) * 2008-01-29 2018-05-07 Fred Hutchinson Cancer Research Center Identificación de células T CD8+ que son CD161 hi y/o IL-18R (alfa) hi y tienen una capacidad de evacuación rápida de fármacos

Similar Documents

Publication Publication Date Title
BE2015C040I2 (enExample)
BR112012008195A2 (enExample)
BRPI0924307A2 (enExample)
BR112012008267A2 (enExample)
BR112012012396A2 (enExample)
BR122021004633A2 (enExample)
BR112012000665A2 (enExample)
BR112012003080A2 (enExample)
BR112012012487A2 (enExample)
BR112012003853A2 (enExample)
BRPI0924534A2 (enExample)
BR112012009797A2 (enExample)
BR112012009446A2 (enExample)
BR112012009703A2 (enExample)
BR112012001263A2 (enExample)
BR112012010357A2 (enExample)
BR112012007656A2 (enExample)
BR112012014856A2 (enExample)
BR112012000159A2 (enExample)
BR112012002627A2 (enExample)
BR112012007654A2 (enExample)
BR112012007672A2 (enExample)
BR112012000156A2 (enExample)
BR112012007671A2 (enExample)
BRPI0925022A2 (enExample)